Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $49.00.

Several equities research analysts recently commented on KYMR shares. Morgan Stanley lifted their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 14th. Leerink Partners restated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a research report on Monday, August 26th. B. Riley raised their price target on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th. Finally, Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th.

Kymera Therapeutics Stock Up 0.3 %

NASDAQ:KYMR opened at $46.56 on Tuesday. The stock has a market cap of $2.86 billion, a price-to-earnings ratio of -18.55 and a beta of 2.21. The company’s 50 day moving average price is $46.54 and its 200-day moving average price is $39.96. Kymera Therapeutics has a 52 week low of $9.60 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The company’s revenue was up 55.2% compared to the same quarter last year. During the same period last year, the business posted ($0.67) EPS. As a group, sell-side analysts anticipate that Kymera Therapeutics will post -2.85 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently bought and sold shares of KYMR. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after purchasing an additional 996,300 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Artal Group S.A. boosted its position in shares of Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after acquiring an additional 496,400 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Kymera Therapeutics by 229.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after purchasing an additional 469,947 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in Kymera Therapeutics in the first quarter worth $17,122,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.